Latest filing published 02 Apr 2025 for Intra-Cellular Therapies, Inc., €6.4M. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
All filings by Mark Neumann on record concern Intra-Cellular Therapies, Inc., in the capacity of finance chief. Over a trading history stretching from 15 October 2021 to 2 April 2025, the count stands at 21 filings.
On the market, this insider has only sold: 3 sales, €1.1M in total. Other entries cover 3 share grants and 14 option exercises.
The newest entry dates from 2 April 2025: a transaction of €6.4M, in Intra-Cellular Therapies, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
21 of 21 declarations